Thermo Fisher Scientifics Advanced Granulation Technology Media Manufacturing Site Expands in Scotland
Essential products needed for the production of biotherapeutics and vaccines for diseases such as influenza and dengue fever will be produced in Scotland, following the launch of the new state-of-the-art facility near Glasgow.
Thermo Fisher Scientific has expanded its campus in Inchinnan, Scotland, with the addition of a cutting-edge facility that will manufacture a novel and proprietary dry media powder known as Gibco Advanced Granulation Technology (AGT). AGT products are animal-origin free, single-component, particulate-free powders for chemically defined cell culture. The AGT dry media format reduces the number of components necessary in cell culture manufacturing processes. Used to manufacture biologics, including vaccines, anti-cancer therapeutics and other life-saving drugs, AGT offers customers the benefits of traditional liquid media without the associated cost, storage, and transportation challenges.
The £14 million investment increases the assurance of supply for customers and complements another Thermo Fisher facility in Grand Island, New York, where AGT is also manufactured. The new facility will add to the Inchinnan site’s existing manufacturing operations, which produce liquid media for a range of research and production applications.
“This is a strategically important facility that will secure supplies for our target markets all over the world,” said Mark Smedley, President of Europe, Middle East and Africa, Life Sciences Solutions, for Thermo Fisher. “It’s important to choose the right location for a factory of this significance, and we felt the depth of experience, skills and expertise at Inchinnan made it the perfect place to make this investment.”
This investment is linked to on-going support from Scottish Enterprise to assist Thermo Fisher in expanding the company’s global manufacturing network.
"Congratulations to Thermo Fisher on the opening of their impressive new facility at Inchinnan,” said Paul Lewis, Managing Director, Scottish Development International and Scottish Enterprise International Operations. "Scotland is already home to a thriving life sciences cluster which is recognised worldwide as one of the most accessible, well-connected and collaborative in Europe. It is major investments like this that allow us to continue to attract ambitious, international companies such as Thermo Fisher to not only locate in Scotland but to strengthen their business base here and to invest in long-term growth."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance